Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Large Molecule Therapeutics

Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian and Huadan Xue
Ting Sun
1Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
2CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjia Zhang
1Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
2CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Li
1Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengyu Jin
1Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Du
2CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
3The University of Chinese Academy of Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bjdanna95@hotmail.com jie.tian@ia.ac.cn yang.du@ia.ac.cn
Jie Tian
2CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
3The University of Chinese Academy of Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bjdanna95@hotmail.com jie.tian@ia.ac.cn yang.du@ia.ac.cn
Huadan Xue
1Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bjdanna95@hotmail.com jie.tian@ia.ac.cn yang.du@ia.ac.cn
DOI: 10.1158/1535-7163.MCT-19-0495 Published March 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Postoperative tumor recurrence and metastasis remain an extreme challenge in breast cancer. Therapies that target cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have provided unprecedented clinical benefits in various types of cancer. The aim of this study was to determine whether the combination of anti-CTLA-4 and anti-PD-1 could prevent postoperative breast tumor recurrence and metastasis in breast tumor–bearing mice. The results indicated that the combination of CTLA-4 and PD-1 inhibitors was more effective compared with single inhibitors for mammary tumor growth and prevention of postsurgical tumor recurrence and pulmonary metastasis (P < 0.05), which resulted in prolonged survival (P < 0.05). Analysis of the underlying mechanism revealed that anti-CTLA-4 and anti-PD-1 in combination synergistically promoted the infiltration of CD8+ and CD4+ T cells into tumors (P < 0.05 vs. single inhibitors), thus boosting the antitumor immune responses. In summary, our results revealed that combination immunotherapy with anti-CTLA-4 and anti-PD-1 may present a new, promising regimen to inhibit postoperative breast cancer relapse and lung metastasis and improve patient outcomes, which warrants further investigation in clinical settings.

Introduction

Breast cancer is one of the most frequent cancer types for women, which has the highest incidence rate among new cancer cases, ranking the second important cause of death in women with malignant tumors (1). Surgical removal is considered as the standard treatment for resectable breast cancer and some of prospective randomized trials have proven that surgery combined with adjuvant therapies such as radiation, endocrine therapy, and chemotherapy can reduce the residual risk of recurrence and prolong overall survival of patients (2–4). However, although surgery plus adjuvant or neoadjuvant therapy have shown promising results in clinical studies, the 5-year recurrence risk indicative of treatment failure remains 7% to 13% (5). Therefore, new therapeutic regimens to prevent postoperative breast cancer relapse are in demand.

It has been shown that breast cancer tumors have higher infiltration of immune cells compared with normal breast tissue (6). As indicated by several clinical trials, in certain subtypes of breast cancer, especially in triple-negative breast cancer (TNBC), high levels of tumor-infiltrating lymphocytes (TIL) are strongly correlated with patients' recurrence-free survival and predict favorable outcomes, thus serving as an effective prognostic biomarker (7–11). These findings suggest that to inhibit postoperative tumor recurrence and metastasis, therapies should aim to activate host antitumor immune responses. Therefore, immunotherapy should provide a solution to a problem of improving patients' outcome in TNBC.

Indeed, immunotherapy enabled to achieve promising clinical responses in patients with several types of solid tumors and has attracted considerable attention as a viable therapeutic approach in cancer (12–14). In recent years, clinical application of immune checkpoint inhibitors in cancer has increased. Among them, immunotherapy inhibitors against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1), which promote migration of TILs to tumor sites, demonstrated remarkable efficacy in patients with various cancers such as non–small cell lung cancer, advanced melanoma, and urothelial carcinoma (13, 15, 16). Furthermore, combined treatment with anti-CTLA-4 and anti-PD-1 has demonstrated satisfactory preliminary results, including the application in advanced melanoma, prostate cancer, and renal caner (17–19). Because of limited benefit from monotherapy in breast cancer, current efforts focus on developing promising immunotherapy combinations are now being investigated in the clinically early stage. Recently, two clinical trials are underway, evaluating the efficacy of the combination of anti-CTLA-4 and anti-PD-1 in BC (NCT02536794, NCT03789110), and a follow up study focus on the synergistic effect between anti-CTLA-4 and anti-PD-1 and other agents (e.g., chemotherapy, cytokine, cryoablation) may provide new approaches to further increase responses (NCT02983045, NCT03409198, NCT02833233). Results from combining chemotherapy with both anti-CTLA-4 and anti-PD-1 significantly prolongs survival in BRCA1-mutated breast cancer mice, suggesting a promising therapeutic strategy for breast cancer (20). These completed or ongoing studies mentioned above suggest that combination immunotherapy may elicit synergistic effects and enhance antitumor responses through regulation of the immune system. Tolerance of tumor-specific T cells overexpressing inhibitor receptors, including CTLA-4 and PD-1, is responsible for the immunosuppressive environment, which prevents elimination of cancer cells (21, 22). The antitumor mechanisms elicited by immune checkpoint molecules are different; thus, CTLA-4 is believed to primarily regulate the early stage of T-cell proliferation in lymph nodes, whereas PD-1 mainly suppresses the later stage of T-cell–mediated immune response in the tumor microenvironment (23). Therefore, the combined application of CTLA-4 and PD-1 inhibitors should elicit a synergetic effect, accounting for the effectiveness of combination immunotherapy at the molecular level.

A previous report indicated that anti-CTLA-4 adjuvant therapy was successful in reducing tumor recurrence after resection of primary tumors in prostate cancer (24), suggesting that immunotherapy is a potential solution to prevent cancer relapse through activation of the inhibited immune system and elimination of residual cancer cells. However, this approach to suppress postsurgical tumor recurrence has yet to be evaluated in TNBC. The aim of this study was to determine the effectiveness of combined immunotherapy with anti-CTLA-4 and anti-PD-1 in preventing TNBC recurrence after mastectomy using a mouse model of TNBC (25) and noninvasive fluorescence and bioluminescence imaging (BLI) methods (26). Our results show that the combined immunotherapy with these immune checkpoint inhibitors can inhibit breast tumor growth, prevent postsurgical cancer relapse, and increase survival of breast tumor bearing mice.

Materials and Methods

Cell culture and establishment of a breast tumor mouse model

The mouse TNBC cell line 4T1-fLuc used in this study was derived from the mouse mammary carcinoma cell line 4T1 (ATCC) transfected with the luciferase gene. As shown in our previous study, orthotopic 4T1 cell-derived tumors are prone to pulmonary metastasis and were used here to establish a TNBC mouse model (25). Cells were cultured in RPMI1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% FBS (Gibco, Thermo Fisher Scientific) at 37°C in a 5% CO2 incubator. The 4T1-fLuc cells (1 × 106) were suspended in PBS (Gibco, Thermo Fisher Scientific) and injected into the left mammary gland or subcutaneously into the right hind back of female BALB/c mice (20–25 g, 5–6 weeks; Vital River Laboratory Animal Technology Co. Ltd.). All experimental protocols were approved by Peking Union Medical College Hospital (PUMCH), and all efforts were made to minimize animal sufferings.

Animal surgery

Surgery was performed when the tumor volume reached about 100 to 150 mm3. Mice were anesthetized with 2% isoflurane and spontaneous breathing was maintained. Fur surrounding the incision site was removed with aseptic preparation of surgical site with twice iodophor disinfectant. One of the two doctors performed surgeries with sterilized surgical instruments in the procedure room. Small incisions were sutured quickly and mice were returned to cages after waking up. BLI (IVIS Imaging Spectrum System) was used to examine tumor residues. The postoperative mice were randomly divided into different treatment groups.

Anti-CTLA-4 and anti-PD-1 treatment

All tumor-bearing mice in need of immunotherapy were randomly divided into four treatment groups: (i) PBS (vehicle), (ii) anti-PD-1, (iii) anti-CTLA-4, and (iv) combined anti-PD-1+anti-CTLA-4 therapeutic group. To evaluate the effect of immunotherapy on preventing postoperative recurrence, 40 mice (n = 10 per group) were randomly divided into the above four groups. Postoperative immunotherapy was started immediately after surgery by intraperitoneal injection of 100 μg anti-CTLA-4 (InVivoMab anti-mouse CTLA-4; BioXCell) and/or 200 μg anti-PD-1 (InVivoMab anti-mouse PD-1; BioXCell) twice a week for 3 weeks; the control group was administered an equivalent volume of PBS. Injections were performed by another doctor blinded to the drug administered. For orthotopic tumor treatment without surgery, mice (n = 10 per group) were injected the same doses of anti-CTLA-4 and/or anti-PD-1 as mentioned above 3 days after tumor cell implantation when a palpable tumor formed.

In vivo monitoring of the immunotherapeutic effect and postsurgical pulmonary metastasis by BLI

At the end of the treatment period, a total of 24 mice (n = 6 per group) were administered D-luciferin solution (40 mg/mL; Biotium) by intraperitoneal injection prior to imaging and sacrificed to examine pulmonary metastasis by BLI. Bioluminescence intensity was expressed as photons (p)/cm2/s.

Body weight and survival monitoring

Mouse body weight was measured using an automatic weighing scale twice a week during treatment. Survival time was recorded for postoperative and orthotopic tumor-bearing mice.

Synthesis and characterization of CTLA-4-IRDye800CW and PD-1-IRDye800CW

The CTLA-4-IRDye800CW was prepared by conjugating IRDye800CW succinimidyl ester (LiCor Biosciences) to anti-CTLA-4 mAb. The connection of IRDye800CW and the anti-CTLA-4 mAb was performed according to the IRDye800CW Labeling Kit from LI-COR Corporate according to the manufacturer's instructions. UV-Vis spectrophotometer was used to determine the IRDye800CW-conjugated protein mAb concentrations and the labeling degree. Briefly, the anti-CTLA-4 mAb was first concentrated using centrifugal Ultra-2 filter of 10 kDa to achieve concentration of ∼8.75 mg/mL. The anti-CTLA-4 mAb (10 nmol, 1 mL, 0.01 mmol/L) was diluted with borate buffer (pH 8.5–9.0) and reacted with aqueous IRDye800CW succinimidyl ester (40 nmol, 0.005 mL, 8 mmol/L), and the resulting solution was incubated at room temperature for 1.5 hours. Finally, the purification was performed by centrifugation filter through 10 kDa and washing repeatedly with PBS (pH 7.4) until no free IRDye800CW was detected in the filtrate. The fluorescence probe was then stored at −4 °C before use. PD-1-IRDye800CW and IgG-IRDye800CW were also prepared using similar method. The characterization of the probes was shown in the Supplementary Information.

Biodistribution and FMI with CTLA-4-IRDye800CW and PD-1-IRDye800CW

The dynamic biodistribution of CTLA-4-IRDye800CW and PD-1-IRDye800CW in 4T1-fLuc breast tumor bearing mice was assessed by noninvasive in vivo FMI using the IVIS Imaging Spectrum System and the corresponding software (version 3.0). BLI was performed prior to FMI to confirm tumor location. FMI was carried out from 0 to 48 hours after tail vein injection of CTLA-4-IRDye800CW and PD-1-IRDye800CW probes; the control group was injected IgG-IRDye800CW. A total of 18 mice (n = 6 per group) were randomly divided into three groups to evaluate FMI biodistribution in vivo. Mice were sacrificed by cervical dislocation 24 hours after in vivo imaging, and tissues including the brain, heart, liver, spleen, kidney, and tumors were harvested for ex vivo FMI. The tumor-to-background ratio (TBR) was calculated according to the following formula: TBR = Fluorescence light intensitytumor/Fluorescence light intensitymuscle.

Multispectral imaging analysis

In the multispectral immunofluorescence staining, tumors dissected after the treatment were fixed in 4% formaldehyde solution, sectioned at 4-μm thickness, and stained with the PerkinElmer Opal Kit (Perkin Elmer). Three tumor specimens were collected in each treatment group and three discontinuous slices were stained for each specimen. The technician randomly selected three views to quantify the percentage of CD3+CD8+ and CD3+CD4+ T cells on each slice. Slides were scanned using the PerkinElmer Vectra system (Perkin Elmer) and images were analyzed with the PerkinElmer advanced image analysis software 3.0. Rabbit antimouse CD8, CD4, and CD3 mAbs (ab209775, ab183685, and ab5690, respectively; Abcam) were used for multispectral immunofluorescence staining.

Statistical analysis

GraphPad Prism (version 5.0) was used for statistical analysis. Mouse survival was evaluated by Kaplan–Meier analysis and log-rank test with Bonferroni correction. The tumor volume was analyzed using a two-way ANOVA with multiple comparisons. One-way ANOVA with Tukey test was used for multiple group comparison. P < 0.05 was considered statistically significant.

Results

Targeted FMI of CTLA-4 and PD-1 expression in 4T1 tumor xenografts

Before injecting CTLA-4-IRDye800CW and PD-1-IRDye800CW fluorescence probes, tumor location was identified by BLI. The characterization of CTLA-4-IRDye800CW and PD-1-IRDye800CW probes were shown in supplemental results (Supplementary Fig. S1–S3). Results of FMI performed at different time points revealed that CTLA-4-IRDye800CW and PD-1-IRDye800CW started to appear at the tumor sites 4-hour postinjection, accumulated from 4 to 8 hours, and then steadily decreased from 12 to 48 hours. At 48-hour postinjection, the CTLA-4-IRDye800CW and PD-1-IRDye800CW signals could still be detected at the tumor location (Fig. 1A). Similarly, in the IgG-IRDye800CW control group, the tumor-localized signal was observed at 4 hours after probe injection and gradually increased from 4 to 8 hours, but cannot be detected at 48-hour postinjection (Fig. 1A). To further validate the in vivo results, mice were sacrificed and tumors and major organs dissected at 24-hour postinjection. Ex vivo FMI analysis indicated that fluorescence signals of the targeted probes in tumors were stronger than that of the control probe (Fig. 1B). Quantification of the TBR revealed that the signals produced by the CTLA-4-IRDye800CW and PD-1-IRDye800CW probes were more specific and stable within tumor tissues than that of the control probe, and their intensity at the peak point (8 hours) was about two times higher (P < 0.05; Fig. 1C). Thus, FMI can be used for direct visualization of dynamic tumor CTLA-4 and PD-1 expression in vivo.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Biodistribution of CTLA-4-IRDye800CW, PD-1-IRDye800CW, and IgG-IRDye800CW in 4T1-fLuc breast tumor–bearing mice. Probes were injected into breast heterotopic tumor–bearing mice (n = 6 per group); fluorescence was analyzed by FMI at the indicated time points. A, In vivo sequential time point imaging. B, Ex vivo biodistribution of fluorescent probes in tumors and organs at 24 hours. C, Quantitative analysis of the tumor-to-background fluorescence ratio in vivo. *, P < 0.05.

Suppression of orthotopic 4T1 tumor growth by the combination of anti-CTLA-4 and anti-PD-1

BLI analysis revealed that bioluminescence intensity was significantly decreased in tumors of mice treated with anti-CTLA-4 or anti-PD-1 compared with control (PBS) mice; the decrease was especially pronounced in the combined treatment group (P < 0.01 vs. control and P < 0.05 vs. single inhibitor groups; Fig. 2A and B). The results of tumor volume measurements were consistent with BLI observations (Fig. 2C). Overall, these findings suggest that the use of CTLA-4/PD-1 immune checkpoint inhibitors as a combined treatment regimen provides effective suppression of breast tumor growth.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The effect of combination therapy with anti-CTLA-4 and anti-PD-1 on orthotopic 4T1 tumor growth. Mice were inoculated with tumor cells into the mammary gland and treated with PBS (control), anti-CTLA-4, anti-PD-1, or anti-CTLA-4+anti-PD-1 for 18 days (n = 10 mice per group). A, Continuous observation of the therapeutic effect by BLI. Bioluminescence intensity (B) and tumor volume (C). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Analysis of TILs in the tumor microenvironment after immunotherapy

To address the immune mechanisms underlying breast tumor inhibition by anti-CTLA-4/anti-PD-1, we analyzed T-cell infiltration into the tumor microenvironment after immunotherapy by multispectral imaging (Fig. 3A and B). The results showed that mice treated with the immune checkpoint inhibitors had significantly increased presence of CD8+ and CD4+ T cells in tumors compared with control; this effect was the highest in the group receiving both anti-CTLA-4 and anti-PD-1 (P < 0.05 vs. single inhibitor groups; Fig. 3C). Furthermore, the accumulation of CD8+ T cells at the tumor margin was also increased in all treatment groups compared with control and was significantly higher in the combination group compared with anti-PD-1 treatment group (P < 0.05; Fig. 4).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Analysis of TILs by multiplexed immunofluorescence. A, Multispectral imaging after treatment: CD3 (red), CD8 (green), CD4 (cyan), and DAPI (blue). Scale bar, 100 μm. B, Representative image of a tumor with high TIL infiltration after combination immunotherapy. The inset presents a magnified view of an area with high numbers of CD3+CD8+ (arrows) and CD3+CD4+ (asterisks) T cells. C, Quantitative analysis of CD3+CD8+ and CD3+CD4+ T-cell infiltration in tumors (n = 3). *, P < 0.05; **, P < 0.01. ns, not significant.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

CD8+ T-cell accumulation at the tumor margin with different treatments. A, Representative images of tumors from the indicated groups. B, Quantitative analysis of CD8+ T cells at the tumor margin. *, P < 0.05. ns, not significant.

Combined application of anti-CTLA-4 and anti-PD-1 reduces orthotopic tumor recurrence and prolongs survival after surgery

Our data indicated that the CTLA-4 and PD-1 inhibitors in combination could synergistically suppress orthotopic breast tumor growth, suggesting a new treatment regimen for TNBC therapy. We further examined the effects of the combination immunotherapy on orthotopically postsurgical tumor recurrence using BLI. The results showed that tumor recurrence was observed 6 days after surgery in 60% mice of the PBS and anti-PD-1 groups; however, bioluminescence intensity in the PBS group increased more rapidly than the anti-PD-1 group (Fig. 5A and B). In the anti-CTLA-4 group, tumor recurrence was fist observed 12 days after surgery in 60% mice, whereas in the combination group, only 10% mice had tumor recurrence at the end of the observation period (18 days; Fig. 5A and B), indicating that the combination immunotherapy could significantly inhibit cancer relapse. Survival analysis further confirmed the effectiveness of anti-CTLA-4/anti-PD-1 combination in suppressing TNBC progression. The survival time in the combination group was significantly prolonged compared not only with control but also with the single inhibitor-treated groups (P < 0.05, Fig. 5C).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Combined treatment with anti-CTLA-4 and anti-PD-1 reduced postsurgical tumor recurrence and prolonged survival. Orthotopic mammary tumors were removed and mice were treated with PBS (control), anti-CTLA-4, anti-PD-1, or anti-CTLA- 4+anti-PD-1 for 18 days (n = 10 mice per group). A, Tumor recurrence after surgery monitored by BLI. B, Quantitative analysis of tumor bioluminescence intensity by BLI. C, Kaplan–Meier survival curves showing treatment response. *, P < 0.05; **, P < 0.01.

As incomplete breast tumor resection may result in the invasion of cancer cells into the surrounding tissues, we also analyzed the effects of the immune checkpoint inhibitors in a subcutaneous tumor model. The results revealed that the combination of immune checkpoint inhibitors could slow tumor growth and in some cases even eliminate residual tumors (Supplementary Figs. S4A and S4B). The combination treatment group also had a better survival rate than the control and single inhibitor groups (Supplementary Fig. S4C). These findings indicate that the combined application of CTLA-4 and PD-1 inhibitors is a promising strategy to prevent postsurgical tumor recurrence in TNBC.

Combination of anti-CTLA-4 and anti-PD-1 prevents lung metastasis of 4T1 tumors

As 4T1 cell-derived breast tumors are characterized by frequent lung metastasis (25), we investigated the effect of immunotherapy on the inhibition of pulmonary metastasis after surgery both in vivo and ex vivo. BLI revealed that in the control group, 5 of 6 mice had metastatic lesions in the lung, which progressed rapidly during the treatment period, whereas in the single inhibitor-treated groups, 4 of 6 mice developed lung metastasis and pulmonary lesions grew slower than in the control group (Fig. 6A and B). In contrast, only 1 of 6 mice appeared to have lung lesions in the combination group at the end of treatment (Fig. 6A and B). Quantitative analysis indicated that the anti-CTLA-4 and anti-PD-1 combination treatment group had the lowest luminescence signal intensity in lung metastatic tumors (P < 0.05 vs. single inhibitor groups; Fig. 6C). There was no significant body weight loss during the treatment course (Supplementary Fig. S5), suggesting that the dosing regimen was relatively well tolerated and safe.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Combined treatment with anti-CTLA-4 and anti-PD-1 prevented lung metastasis of 4T1 tumors. Orthotopic mammary tumors were removed and mice were treated with PBS (control), anti-CTLA-4, anti-PD-1, or anti-CTLA-4+anti-PD-1 for 18 days (n = 6 mice per group). A, Postsurgical pulmonary metastasis analyzed by in vivo BLI. B, Pulmonary metastasis analyzed by ex vivo BLI. C, Quantitative analysis of bioluminescence intensity. *, P < 0.05. ns, not significant.

Discussion

Postoperative recurrence in TNBC remains a challenging problem due to cancer resistance to therapies and/or tumor metastasis. Therefore, novel effective treatment, including combination therapy that can elicit good response in patients with TNBC are urgently needed. Recent clinical trials present compelling evidence that immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1 can provide efficient and durable tumor control by stimulating antitumor immune response in patients. In this study, we proved that the combination of anti-CTLA-4 and anti-PD-1 caused synergistic antitumor effects superior to those of the single inhibitors and that the underlying mechanism is based on increased infiltration of CD8+ and CD4+ T cells in breast tumors. Moreover, we found that the combined immunotherapy could also inhibit postsurgical tumor recurrence and metastasis.

Rational combination immunotherapy has already been applied to patients with advanced non–small cell lung cancer and melanoma, who showed longer progression-free survival (PFS) and higher objective response rates after receiving anti-CTLA-4 together with anti-PD-1 compared with those treated with the single inhibitors (27, 28). As breast cancer is considered a low-immunogenicity cancer because of moderate mutational load, it does not elicit a sufficient antitumor immune response, which should be stimulated by appropriate therapy. Our present results indicate that anti-CTLA-4 and anti-PD-1 in combination exhibited significantly stronger suppression of orthotopic breast tumor growth compared with the single inhibitors, indicating a more powerful effect of combination therapy. Moreover, using in vivo and ex vivo FMI we revealed that fluorescently labeled CTLA-4 and PD-1 probes were preferentially accumulated in 4T1 cell-derived tumors, suggesting that immunotherapy with these immune checkpoint inhibitors could be effective.

Currently, response evaluation criteria (RECIST) and WHO classification of solid tumor have become general acceptance criteria despite imperfection. Patients treated by immunotherapy may experience tumor pseudo-progression (29), which has led to the development of immune-specific response guidelines such as immunotherapy RECIST (iRECIST). Many patients benefited from immunotherapy; however, there are no proven biomarkers to exactly predict the effect of immune checkpoint inhibitors (9). A study of immunotherapy in patients with metastatic melanoma treated with anti-PD-1 showed that the intratumoral density of CD8+ T cells could serve as a prognostic criterion of favorable treatment response (9, 30). In patients with TNBC, the density of CD8+ T cells was highly related to TILs, which can predict patients' pathologic complete response (pCR; refs. 9, 31). Similar results were also shown in desmoplastic melanomas and synovial sarcoma (32, 33). Furthermore, the increased CD8+ T cell density at the invasive tumor margin was identified as the best biomarker for treatment response to immune checkpoints inhibitors (30). In our study, we observed that tumor infiltration of CD8+ and CD4+ T cells and accumulation of CD8+ T cells at the tumor margin were increased in mice treated with the combination of anti-CTLA-4 and anti-PD-1 compared with monotherapy, suggesting that the effects of the combination immunotherapy in TNBC are due to the activation of TILs.

A previous study showed that a lower recurrence rate and longer pCR after surgery correlated with higher infiltration of TILs (9, 31, 34). Consistent with these data, our results indicated that the combined treatment with CTLA-4 and PD-1 inhibitors prolonged survival compared with monotherapy, which corresponded to increased CD8+ T-cell infiltration. For the patients with metastatic breast cancer, primary tumor resection can reduce tumor burden and improve the survival time (35), followed by chemotherapy or radiotherapy aimed to prevent tumor recurrence and metastasis. In our study, we observed that the dual immunotherapy can inhibit cancer relapse and pulmonary metastasis characteristic for TNBC and improve survival after the removal of primary tumors, indicating that immunotherapy with CTLA-4/PD-1 inhibitors can eliminate residual lesions. The majority of lung metastasis cases are currently treated with radiotherapy, chemotherapy, and video-assisted thoracoscopic surgery (36), and our results on the regression of pulmonary lesions suggest that the combination immunotherapy may provide a new treatment method for patients with pulmonary micro-metastasis to improve PFS.

However, it should be noted that the increasing application of anti-CTLA4 and anti-PD-1 has raised a question of immune-related adverse events (irAE). Previous studies revealed that 75% of patients treated with CTLA-4 inhibitors developed all-grade irAEs, which were dose dependent (37), whereas patients treated with PD-1/PD-L1 inhibitors had a ≤30% risk of developing irAEs (38–40). The irAEs were shown to increase by the dual immunotherapy. Thus, the incidence of diarrhea, which is one of the most common irAEs, was higher in patients receiving the combination of anti-CTLA-4 and anti-PD-1 inhibitors (41), which can also lead to a higher risk of pneumonitis (42), arthritis (43), and neurologic complications (44) compared with single-agent therapy. Therefore, long-term management of irAEs should be considered for patients treated with combinatorial immunotherapy.

Although orthotopic 4T1 mouse model is a powerful representative to research immunotherapy in TNBC, it does not represent every subtypes of breast cancer. Certain types of breast cancer respond differently even to the same immunotherapy inhibitors. In summary, our results revealed that the dual immunotherapy with anti-CTLA-4 and anti-PD-1 can suppress orthotopic breast tumor growth and prevent postsurgical cancer relapse, resulting in extended survival of 4T1-fLuc breast tumor bearing mice. In this study, we used highly sensitive optical imaging methods to monitor the therapeutic effect of combination immunotherapy, including multispectral imaging technology which enabled detection of different types of immune cells infiltrating tumor sites. Our study demonstrates that the combined application of anti-CTLA-4 and anti-PD-1 provides a new treatment strategy to prevent postoperative tumor recurrence by promoting infiltration of CD4+ and CD8+ T cells in tumors. Thus, the combinatorial immunotherapy, in particular with anti-CTLA-4 and anti-PD-1, is a promising treatment strategy in TNBC, which should be further evaluated in clinics.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: Y. Du, J. Tian, H. Xue

Development of methodology: Y. Du, J. Tian

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Sun, W. Zhang, Y. Li

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Sun

Writing, review, and/or revision of the manuscript: T. Sun, Z. Jin, Y. Du, J. Tian, H. Xue

Study supervision: Y. Du, J. Tian, H. Xue

Acknowledgments

This work was supported by the grants from the National Key Research and Development Plan of China (grant number 2017YFA0205200); National Natural Science Foundation of China (grant numbers 81371608, 81871514, 81470083, 81227901); Beijing Natural Science Foundation (grant number 7172170); National Public Welfare Basic Scientific Research Project (grant number 2017PT32004); and Chinese Academy of Medical Sciences Students' Innovation Foundation (grant number 1007-1002-1-12). The authors would like to acknowledge the instrumental and technical support of multimodal biomedical imaging experimental platform, Institute of Automation, Chinese Academy of Sciences.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Mol Cancer Ther 2020;19:802–11

  • Received May 18, 2019.
  • Revision received September 25, 2019.
  • Accepted November 25, 2019.
  • Published first December 3, 2019.
  • ©2019 American Association for Cancer Research.

References

  1. 1.↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dieras V,
    2. Miles D,
    3. Verma S,
    4. Pegram M,
    5. Welslau M,
    6. Baselga J,
    7. et al.
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:732–42.
    OpenUrl
  3. 3.↵
    1. Houghton J
    . Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet North Am Ed 2003;362:95–102.
    OpenUrl
  4. 4.↵
    1. Cuzick J,
    2. Sestak I,
    3. Pinder SE,
    4. Ellis IO,
    5. Forsyth S,
    6. Bundred NJ,
    7. et al.
    Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21–9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Brewster AM,
    2. Hortobagyi GN,
    3. Broglio KR,
    4. Kau SW,
    5. Santa-Maria CA,
    6. Arun B,
    7. et al.
    Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100:1179–83.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ruffell B,
    2. Au A,
    3. Rugo HS,
    4. Esserman LJ,
    5. Hwang ES,
    6. Coussens LM
    . Leukocyte composition of human breast cancer. PNAS 2012;109:2796–801.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Denkert C,
    2. von Minckwitz G,
    3. Darb-Esfahani S,
    4. Lederer B,
    5. Heppner BI,
    6. Weber KE,
    7. et al.
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40–50.
    OpenUrl
  8. 8.↵
    1. Afghahi A,
    2. Purington N,
    3. Han SS,
    4. Desai M,
    5. Pierson E,
    6. Mathur MB,
    7. et al.
    Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 2018;24:2851–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Savas P,
    2. Salgado R,
    3. Denkert C,
    4. Sotiriou C,
    5. Darcy PK,
    6. Smyth MJ,
    7. et al.
    Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 2016;13:228–41.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Adams S,
    2. Gray RJ,
    3. Demaria S,
    4. Goldstein L,
    5. Perez EA,
    6. Shulman LN,
    7. et al.
    Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959–66.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Ali HR,
    2. Provenzano E,
    3. Dawson SJ,
    4. Blows FM,
    5. Liu B,
    6. Shah M,
    7. et al.
    Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 2014;25:1536–43.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Ribas A,
    2. Hamid O,
    3. Daud A,
    4. Hodi FS,
    5. Wolchok JD,
    6. Kefford R,
    7. et al.
    Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600–9.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Robert C,
    2. Schachter J,
    3. Long GV,
    4. Arance A,
    5. Grob JJ,
    6. Mortier L,
    7. et al.
    Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–32.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Pardoll DM
    . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Reck M,
    2. Rodriguez-Abreu D,
    3. Robinson AG,
    4. Hui R,
    5. Csoszi T,
    6. Fulop A,
    7. et al.
    Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Bellmunt J,
    2. de Wit R,
    3. Vaughn DJ,
    4. Fradet Y,
    5. Lee JL,
    6. Fong L,
    7. et al.
    Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lu X,
    2. Horner JW,
    3. Paul E,
    4. Shang X,
    5. Troncoso P,
    6. Deng P,
    7. et al.
    Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017;543:728–32.
    OpenUrlCrossRef
  18. 18.↵
    1. Motzer RJ,
    2. Tannir NM,
    3. McDermott DF,
    4. Aren Frontera O,
    5. Melichar B,
    6. Choueiri TK,
    7. et al.
    Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Wolchok JD,
    2. Chiarion-Sileni V,
    3. Gonzalez R,
    4. Rutkowski P,
    5. Grob JJ,
    6. Cowey CL,
    7. et al.
    Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345–56.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Nolan E,
    2. Savas P,
    3. Policheni AN,
    4. Darcy PK,
    5. Vaillant F,
    6. Mintoff CP,
    7. et al.
    Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med 2017;9. doi: 10.1126/scitranslmed.aal4922.
  21. 21.↵
    1. Mellman I,
    2. Coukos G,
    3. Dranoff G
    . Cancer immunotherapy comes of age. Nature 2011;480:480–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Drake CG,
    2. Jaffee E,
    3. Pardoll DM
    . Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51–81.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Buchbinder EI,
    2. Desai A
    . CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98–106.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Kwon ED,
    2. Foster BA,
    3. Hurwitz AA,
    4. Madias C,
    5. Allison JP,
    6. Greenberg NM,
    7. et al.
    Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci 1999;96:15074–9.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Aslakson CJ,
    2. Miller FR
    . Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399–405.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Weissleder R,
    2. Pittet MJ
    . Imaging in the era of molecular oncology. Nature 2008;452:580–9.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Larkin J,
    2. Chiarion-Sileni V,
    3. Gonzalez R,
    4. Grob JJ,
    5. Cowey CL,
    6. Lao CD,
    7. et al.
    Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Antonia S,
    2. Goldberg SB,
    3. Balmanoukian A,
    4. Chaft JE,
    5. Sanborn RE,
    6. Gupta A,
    7. et al.
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299–308.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Chiou VL,
    2. Burotto M
    . Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541–3.
    OpenUrlFREE Full Text
  30. 30.↵
    1. Tumeh PC,
    2. Harview CL,
    3. Yearley JH,
    4. Shintaku IP,
    5. Taylor EJ,
    6. Robert L,
    7. et al.
    PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Denkert C,
    2. von Minckwitz G,
    3. Brase JC,
    4. Sinn BV,
    5. Gade S,
    6. Kronenwett R,
    7. et al.
    Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015;33:983–91.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Eroglu Z,
    2. Zaretsky JM,
    3. Hu-Lieskovan S,
    4. Kim DW,
    5. Algazi A,
    6. Johnson DB,
    7. et al.
    High response rate to PD-1 blockade in desmoplastic melanomas. Nature 2018;553:347–50.
    OpenUrlPubMed
  33. 33.↵
    1. Nowicki TS,
    2. Akiyama R,
    3. Huang RR,
    4. Shintaku IP,
    5. Wang X,
    6. Tumeh PC,
    7. et al.
    Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res 2017;5:118–26.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Bianchini G,
    2. Balko JM,
    3. Mayer IA,
    4. Sanders ME,
    5. Gianni L
    . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674–90.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Shien T,
    2. Kinoshita T,
    3. Shimizu C,
    4. Hojo T,
    5. Taira N,
    6. Doihara H,
    7. et al.
    Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep 2009;21:827–32.
    OpenUrlPubMed
  36. 36.↵
    1. Dong S,
    2. Zhang L,
    3. Li W,
    4. Du J,
    5. Liu X,
    6. Chen X
    . Evaluation of video-assisted thoracoscopic surgery for pulmonary metastases: a meta-analysis. PLoS One 2014;9:e85329.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Bertrand A,
    2. Kostine M,
    3. Barnetche T,
    4. Truchetet ME,
    5. Schaeverbeke T
    . Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Maughan BL,
    2. Bailey E,
    3. Gill DM,
    4. Agarwal N
    . Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol 2017;7:56.
    OpenUrl
  39. 39.↵
    1. Villadolid J,
    2. Amin A
    . Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4:560–75.
    OpenUrl
  40. 40.↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Puzanov I,
    2. Diab A,
    3. Abdallah K,
    4. Bingham CO 3rd.,
    5. Brogdon C,
    6. Dadu R,
    7. et al.
    Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Naidoo J,
    2. Wang X,
    3. Woo KM,
    4. Iyriboz T,
    5. Halpenny D,
    6. Cunningham J,
    7. et al.
    Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709–17.
    OpenUrl
  43. 43.↵
    1. Suarez-Almazor ME,
    2. Kim ST,
    3. Abdel-Wahab N,
    4. Diab A
    . Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 2017;69:687–99.
    OpenUrl
  44. 44.↵
    1. Cuzzubbo S,
    2. Javeri F,
    3. Tissier M,
    4. Roumi A,
    5. Barlog C,
    6. Doridam J,
    7. et al.
    Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017;73:1–8.
    OpenUrl
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (3)
March 2020
Volume 19, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian and Huadan Xue
Mol Cancer Ther March 1 2020 (19) (3) 802-811; DOI: 10.1158/1535-7163.MCT-19-0495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian and Huadan Xue
Mol Cancer Ther March 1 2020 (19) (3) 802-811; DOI: 10.1158/1535-7163.MCT-19-0495
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Improved Activity of CF10 in Preclinical Colorectal Cancer Models
  • Activity of ABBV-085 in Osteosarcoma
  • An Anti–CD22-seco-CBI-Dimer ADC for the Treatment of NHL
Show more Large Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement